Medicine and Dentistry
Inflammatory Bowel Disease
100%
Personalized Medicine
46%
Crohn's Disease
45%
Patient with Inflammatory Bowel Disease
38%
Ulcerative Colitis
36%
Diseases
34%
Tumor Necrosis Factor
34%
Symptom
33%
Prognostic Factor
31%
Biological Therapy
31%
Inflammatory Disorder
31%
Patient with Crohn's Disease
28%
Endoscopy
27%
Maintenance Therapy
24%
Biological Product
23%
TNF Inhibitor
21%
Patient with Ulcerative Colitis
19%
Outpatient
17%
Colorectal Cancer
15%
Health Care Cost
15%
Collagenous Colitis
15%
Birth Outcomes
15%
Faecal Calprotectin
15%
Esophagus Mucosa
15%
Gastroesophageal Reflux
15%
Colonoscopy
15%
Dysplasia
15%
Randomized Controlled Trial
15%
Patient Care
15%
Placebo
15%
Prospective Cohort Study
15%
Pharmacokinetics
15%
Premedication
15%
Drug Dose Intensification
15%
Infliximab
15%
Azathioprine
15%
Combination Therapy
14%
Fistula
13%
Treatment Response
12%
Adalimumab
11%
Colitis
11%
Bland-Altman Plot
10%
Consultation
10%
Kappa Statistics
10%
Drug Therapy
9%
Biopsy
9%
Spondylarthritis
8%
Hidradenitis Suppurativa
8%
Psoriasis
8%
Uveitis
8%
Pharmacology, Toxicology and Pharmaceutical Science
Infliximab
62%
Inflammatory Bowel Disease
48%
Crohn's Disease
40%
Adalimumab
27%
Ulcerative Colitis
22%
Tumor Necrosis Factor
21%
Infection
19%
Disease
19%
Irritable Colon
15%
Azathioprine
15%
Standardized Incidence Ratio
15%
Iron Deficiency
15%
Biological Product
15%
Combination Therapy
13%
Fistula
13%
Tumor Necrosis Factor Inhibitor
11%
Mercaptopurine
11%
Immunosuppressive Agent
7%
Symptom
7%
Drug Concentration
5%
Uveitis
5%
Spondylarthritis
5%
Rectum Hemorrhage
5%
Suppurative Hidradenitis
5%
Remission
5%
Keyphrases
Biologic Therapy
15%
Infliximab
15%
6-mercaptopurine (6-MP)
15%
Dose Intensification
15%
Anti-TNF Treatment
15%
Standardized Incidence Ratio
15%
Macroscopic Findings
15%
Patient Phenotype
15%
Microscopic Appearance
15%
Colonoscopy Surveillance
15%
Population-based
15%
Lifestyle Recommendations
15%
Short Health Scale
15%
Premedication
15%
Inflammatory Bowel Disease
15%
Non-academic Hospital
12%
Anti-tumor Necrosis Factor Agents
11%
Maternal Milk
10%
Harvey-Bradshaw Index
9%
Treatment Discontinuation
7%
Complex Fistula
7%
Clinical Markers
7%
Primary Response
7%
Histopathological Findings
7%
Basal Layer
7%
Attached mucosa
7%
Clinical Remission
6%
SCCAI
6%
Treatment during Pregnancy
5%
Lactating Women
5%
Mercaptopurine
5%
Drug Administration
5%
Similar Curves
5%
Anti-infliximab Antibodies
5%
Normal Birth
5%
Maximum Permissible Concentration
5%
Infliximab Failure
5%
Thiopurines
5%
Candidate Gene Expression
5%
Pro-inflammatory Molecules
5%
Hidradenitis Suppurativa
5%